Obesity
Methodology & AI Transparency ⓘ
Obesity Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is obesity? Obesity is a disease that means having too much body fat.
- 2 Real-world patient consensus: Diagnostic registry E66.9: Obesity is managed within Weight & Metabolism.
- 3 Typical cash cost range: Primary evaluation for Obesity incorporates fasting cardiometabolic panels [Obesity E66.9] and symptom diary review.
- 4 Top reported side effects / signs: Key Weight & Metabolism biomarkers for Obesity (E66.9): HOMA-IR Insulin Resistance in Obesity (E66.9: Index) & ALT & Fasting in Obesity (E66.9: Triglycerides) (ALT < 25 U/L; TG < 100 mg/dL (E66.9)).
Ask our AI Specialists anything about Obesity
What Is Obesity?
What is obesity? Obesity is a disease that means having too much body fat. It is different from being overweight, which means weighing too much. Both terms mean that your weight is greater than what's considered healthy for your height. Body Mass Index (BMI) measures how much you weigh compared to how tall you are. An adult who has a BMI of 30 or more is considered to have obesity. Severe obesity is having a BMI of 40 or higher. Obesity increases your risk for many other diseases and health problems, especially if the extra body fat is carried around the waist.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Obesity (E66.9, Weight & Metabolism) reflects TNF-alpha) [Obesity E66.9]. Cross-referenced with NIH MeSH (Obesity), longitudinal control is benchmarked via HOMA-IR Insulin Resistance in Obesity (E66.9: Index).
Common Symptoms & Clinical Signs
- • Physical activity level
- • Ask about your health history , which may include reviewing your weight history, weight-loss efforts, and how physically active you are
- • Presentation of Obesity (E66.9): persistent hunger signaling [Obesity E66.9]
- • Secondary Obesity clinical sign: co-existing blood pressure, in Obesity (E66.9: triglyceride, or fasting)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Obesity Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E66.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Obesity (E66.9: Index) | < 1.4 (E66.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Obesity (E66.9: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E66.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Obesity (E66.9: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E66.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Obesity
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Benzphetamine Hydrochloride Benzphetamine Hydrochloride Generic • RxCUI 904368 | Sympathomimetic Amine Anorectic | 81% | $3.0500 | $ 132.03 /mo |
| Chorionic Gonadotropin Chorionic Gonadotropin Generic • RxCUI 896854 | FDA Prescription Therapeutic Agent | 93% | $250.6695 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Obesity)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Potent incretin-based therapy for: What a 5,140-Participant Study Found The side effects related to semaglutide and tirzepatide were primarily of mild-to-moderate severity and mostly gastrointestinal, which was more frequent during the dose-titration period and leveled off during the treatment period. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2024-05-15 • Meta-Analysis | N = 5,140 | 99/100 | PMID 38463003 ↗ |
| New Insights on Tirzepatide as a novel effective and safe strategy for treating: What a 11,758-Participant Study Found Tirzepatide, as a weight loss drug, significantly reduces BMI, waist circumference and body weight while gastrointestinal adverse reactions need to be vigilant. Frontiers in public health • 2024-01-15 • Meta-Analysis | N = 11,758 | 99/100 | PMID 38356942 ↗ |
| New Insights on Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the: What a 12,300-Participant Study Found GLP-1RAs triggered more gastrointestinal side effects than placebo, with no in-between difference. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2023-03-15 • Meta-Analysis | N = 12,300 | 99/100 | PMID 36579723 ↗ |
| New Insights on GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature: What a 1,250,717-Participant Study Found This meta-analysis is the first to investigate the effects of GLP-1 RAs on a large panel of musculoskeletal health outcomes. Drugs • 2026-10-15 • Meta-Analysis | N = 1,250,717 | 99/100 | PMID 42730869 ↗ |
| New Insights on Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the: What a 1,145-Participant Study Found In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation. JACC. Heart failure • 2025-11-15 • Randomized Controlled Trial | N = 1,145 | 96/100 | PMID 41045908 ↗ |
Obesity Patient Community & “People Like Me” Threads
Filter Obesity community threads and patient logs by age, biological sex, dosage, and treatment duration.